Observational studyCardiovascular and interventional radiology2026
Aspartate Aminotransferase to Platelet Index (APRI) as a Prognostic Factor for Overall Survival After TARE Y90 Resin Microspheres in Primary Liver Cancer Patients: Results from the European, Prospective Observational Study CIRT.
Observational study in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02305459 (CIRSE Registry for SIR-Spheres Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CIRSE Registry for SIR-Spheres Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the prognostic value of the aspartate aminotransferase-to-platelet ratio index (APRI) for overall survival (OS) after transarterial radioembolization (TARE) in patients with intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) from the prospective study CIRT (CIRSE study on SIR-Spheres Therapy). MATERIALS AND
methodsAdult patients treated with TARE Y-90 were included. Baseline, laboratory, treatment, and follow-up data were collected prospectively. Receiver operating characteristic analysis was used to determine optimal APRI cut-offs. OS from the date of TARE was analysed using Kaplan-Meier. Propensity score matching and multivariable Cox regression analyses were performed.
results103 ICC and 377 HCC patients were analysed. Most patients had ECOG 0 (58.3%/61.3%) or 1 (31.1%/31.8%) in the ICC and HCC groups, respectively. Median APRI was 0.5 (IQR: 0.3-0.8) in ICC and 0.8 (IQR: 0.4-1.4) in HCC. Higher APRI values were associated with significantly shorter OS in both cohorts using different thresholds (ICC: APRI > 0.4; HCC: APRI > 0.7). These associations remained significant after propensity score matching and multivariable analysis. APRI was an independent prognostic factor for OS in both ICC (95% CI 1.25-5.23; p = 0.010) and HCC (95% CI 1.04-2.06; p = 0.028). The identified APRI cut-offs were associated with survival differences when body surface area (BSA) and modified BSA dosimetry were used, but not with partition model dosimetry.
conclusionAPRI may be a promising, easily accessible prognostic biomarker for OS after TARE in ICC and HCC patients. Its prognostic value may be influenced by tumour type and counteracted by dosimetry method, supporting further investigation on this topic. Trial registration NCT02305459.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.